

RESEARCH ARTICLE

# Synthesis, cytotoxicity and antitumour mechanism investigations of polyoxometalate doped silica nanospheres on breast cancer MCF-7 cells

Hongqian Cao<sup>1</sup>, Chunyan Li<sup>1</sup>, Wen Qi<sup>1</sup>, Xiangjun Meng<sup>1</sup>, Rui Tian<sup>1</sup>, Yanfei Qi<sup>1\*</sup>, Wei Yang<sup>2\*</sup>, Juan Li<sup>1\*</sup>

**1** School of Public Health, Jilin University, Changchun, Jilin, P. R. China, **2** Department of Immunology, Norman Bethune College of Medicine, Jilin University, Changchun, P.R. China

\* [qiyafei@jlu.edu.cn](mailto:qiyafei@jlu.edu.cn) (YQ); [li\\_juan@jlu.edu.cn](mailto:li_juan@jlu.edu.cn) (JL); [ywei@jlu.edu.cn](mailto:ywei@jlu.edu.cn) (WY)



**OPEN ACCESS**

**Citation:** Cao H, Li C, Qi W, Meng X, Tian R, Qi Y, et al. (2017) Synthesis, cytotoxicity and antitumour mechanism investigations of polyoxometalate doped silica nanospheres on breast cancer MCF-7 cells. PLoS ONE 12(7): e0181018. <https://doi.org/10.1371/journal.pone.0181018>

**Editor:** Jamshidkhan Chamani, Islamic Azad University Mashhad Branch, ISLAMIC REPUBLIC OF IRAN

**Received:** April 10, 2017

**Accepted:** June 23, 2017

**Published:** July 13, 2017

**Copyright:** ©2017 Cao et al. This is an open access article distributed under the terms of the [Creative Commons Attribution License](https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

**Data Availability Statement:** All relevant data are within the paper and its Supporting Information files.

**Funding:** This work was financially supported by NSFC (<http://www.nsf.gov.cn/>) (81402719), Young Scholars Program of Norman Bethune Health Science Center of Jilin University (2013202015), and Norman Bethune Program of Jilin University (2015228). The funders had no role in study design, data collection and analysis,

## Abstract

Polyoxometalates (POMs) have shown the potential anti-bacterial, anti-viral and anti-tumor activities. In order to improve their physiological stability and antitumour activity for medical application,  $K_2Na[As^{III}Mo_6O_{21}(O_2CCH_2NH_3)_3] \cdot 6H_2O$  doped silica nanospheres (POM@-SiO<sub>2</sub>) with diameters of ~40 nm have been synthesized by the water-in-oil microemulsion method in this study. The obtained spheres were morphologically uniform nanosized and nearly monodispersed in solution. The nanoparticles had high entrapment efficiency, which was upto 46.2% by the inductively coupled plasma mass spectrometry (ICP-MS) analysis and POMs slowly released from the nanospheres both in the PH 7.4 and 5.5 phosphate buffer saline (PBS) solutions in 60 h. The *in vitro* MTT assays of particles on MCF-7 cell line (a human breast adenocarcinoma cell line) exhibited enhanced antitumor activity compared to that of plain polyoxometalate. The IC<sub>50</sub> value of the POM@SiO<sub>2</sub> nanoparticles was 40.0 µg/mL at 24 h calculated by the encapsulated POM concentration, which was much lower comparing to that of  $2.0 \times 10^4$  µg/mL according to the pure POM. And the SiO<sub>2</sub> shells showed low inhibitory effect at the corresponding concentration. Confocal images further indicated the cell morphology changes and necrosis. Flow cytometric analysis showed nanoparticles induced the apoptosis by arresting the cells in S phase and western blot analysis indicated they promoted apoptosis by inhibiting the Bcl-2 protein. Moreover, the study of interactions between human serum albumin (HSA) and the nanoparticles indicated the fluorescence quenching was static, and the nanoparticles were likely to bind to HSA and changed its conformation.

## Introduction

Cancer is a serious public health problem which threatens human health in the world due to the increasing incidence and mortality. And breast cancer is one of the most common types

decision to publish, or preparation of the manuscript.

**Competing interests:** The authors have declared that no competing interests exist.

among other malignancies in women, along with a major cause of mortality worldwide. New cases of breast cancer diagnosed in 2015 accounted for approximately 12% of all new malignancy cases and the mortality accounted for 25% of all cancer cases in women. The United Kingdom had the highest incidence among the top seven countries. Breast cancer undergoes uncontrolled growth and metastasizes to distant sites, such as brain, liver and bone [1]. The worldwide new cases of female breast cancer is estimated to reach nearly 3.2 million per year by 2050 [2]. The incidence increases with age and more than half of cases are 65 years or older [3]. In spite of treatment, >4,000 patients succumbed to the malignancy in the US in 2016 [4]. Despite intensive investigation of breast cancer cell lines, the cellular and molecular mechanisms between MCF-7 cell line and the drug polyoxometalate (POM) are still limited. In the cancer treatment, chemotherapy is a key method during the illness of patients. Some skin peptides obtained from amphibians even have also been demonstrated possessing the anticancer effects [5]. Because of its significance, there has been long standing interest in the development of novel approaches to improve the therapeutic index of chemotherapy.

Polyoxometalates (POMs) are outstanding class of metal-oxide clusters with O-enriched surfaces. Intriguingly, almost any other element can be incorporated into the POM frameworks, and this leads to fascinating structural versatility and rich properties [6]. It is therefore not surprising that POMs have potential applications in a variety of disciplines including catalysis [7–9], materials science [10], chemical analysis and medicine [11], etc. The previous studies have indicated that POMs are significant drug candidates owing to their remarkable antiviral, antibacterial and antitumoral activities [9, 11–17]. For example, a significant anticancer efficacy of  $[\text{NH}_3\text{Pr}^{\text{I}}]_6[\text{Mo}_7\text{O}_{24}]\cdot 3\text{H}_2\text{O}$  was found on MM46 adenocarcinoma and Meth A sarcoma [18, 19]. Liu and her co-workers have investigated high antitumor activity of  $[\text{CoW}_{11}\text{O}_{39}(\text{CpTi})_7]$  on three types of cancer cells: HL-60 (leukemia), SSMC-7721 (liver cancer cell) and HLC (colon cancer cell) [20, 21]. One of the most important reasons that hinders the applicability of POMs in medicine is that many of them are thermodynamically and kinetically unstable at physiological pH and normally degrade into a mixture of inorganic products. Moreover, the excess oxo ligands of POMs lead to highly negatively charged on the surfaces and their sizes are much larger than the small nanometer sized anti-tumor molecules [17, 20–25]. The surface-charge and size characteristics reduce the penetration efficiency and the anti-tumor effect.

Surface modification of POMs with organic molecules is expected to endow the hybrid novel properties, functions or a synergetic effect. This approach has resulted in a considerable quantity of organofunctionalized derivatives, such as alkoxo, organophosphoryl, organosilyl, and organometallic derivatives [26, 27]. Experimental evaluations have already exhibited enhanced antitumour effect of POMs-based organohybrids [21]. An organic ligand offers additional advantages, such as better stability and biocompatibility. Moreover, biologically reasonable organic ligands might tune the bioactivity and cytotoxicity [28]. The encapsulation of nanoparticles with amorphous  $\text{SiO}_2$  shells has become a widely used technique [29, 30]. Owing to high surface area/volume ratio and relatively ease of surface functionalization,  $\text{SiO}_2$  shells are widely used in many fields, including the drug delivery for the controlled release of therapeutics systems [31, 32]. The silica frameworks are different from polymer nanoparticles for their immunity to enzymatic degradation and hydrolysis, as well as their large loadings of drugs [27]. Green et al. synthesized the POM/poly-L-lysine Stöber type  $\text{SiO}_2$  nanosphere, the conjugate led to an appealing system of drug carriers in optical monitoring field [33, 34]. The latter work reported POMs evenly spread throughout the  $\text{SiO}_2$  nanospheres. In general, the nanoparticles with silica coating can be achieved by the Stöber method [35] or the reverse microemulsion synthesis [36]. Human serum albumin (HSA) is a single chain polypeptide which plays a key role in maintaining normal osmolarity in plasma. It is also a main carrier for

various endogenous and exogenous compounds [37, 38]. Although the antitumor activity of POMs has been investigated intensively, the binding actions between core/shell POMs decorated silica nanoparticles and HSA remain limited.

In our previous work, the *in vitro* antitumor activity of  $K_2Na[As^{III}Mo_6O_{21}(O_2CCH_2NH_3)_3] \cdot 6H_2O$  ( $AsMo_6$ ) on lung adenocarcinoma cells (A549) was investigated by the 3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyl-tetrazolium bromide (MTT) assay, the results indicated that the inhibitory effect was higher than that of 5-fluorouracil (5-FU) [39]. And in the study of anti-leukemia, the compound showed low inhibitory effect on normal human umbilical vein endothelial cells (HUVEC) with an  $IC_{50}$  value of 889.18  $\mu M$  and a significant anticancer effect on human HL-60 and U937 leukemia cells [40]. Herein, we aim to evaluate the cytotoxicity of pure POMs and nanoparticles on MCF-7 cell line. The  $K_2Na[As^{III}Mo_6O_{21}(O_2CCH_2NH_3)_3] \cdot 6H_2O$  doped silica nanospheres (POM@SiO<sub>2</sub>) was synthesized by reverse microemulsion method and confirmed by TEM and FT-IR analysis. Furthermore, their release profile was evaluated by ICP-MS. And the morphological changes of MCF-7 cells were detected by confocal laser scanning microscope. In addition, at physiological conditions, the binding interactions of the nanoparticles with HSA were investigated by multispectroscopic techniques.

## Materials and methods

### Reagents and materials

All reagents were obtained from commercial supplies and used without further purification. The  $K_2Na[AsMo_6O_{21}(O_2CCH_2NH_3)_3] \cdot 6H_2O$  (POM), was prepared according to the previously described approach [40]. RPMI-1640 Medium and Fetal bovine serum (FBS) were purchased from Hyclone, 3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide (MTT), phosphate buffer saline (PBS) and HSA were obtained from Sigma-Aldrich. The Propidium Iodide (PI) and Hoechst 33342 dye were obtained from Dingguo Chemicals Company. The solution of HSA was prepared by dissolving the reagent in PBS and stirred for 24 h to get a homogeneous solution. RIPA lysis buffer (Solarbio, China) and antibodies (Abcam) were prepared for the western blot analysis.

### Preparation of POM@SiO<sub>2</sub> nanoparticles

The POM@SiO<sub>2</sub> nanoparticles were prepared by water-in-oil microemulsion method according to the literature with a little modification [41]. A W/O microemulsion containing 9.29 mL cyclohexane, 2.26 mL n-octanol, 2.23 mL Triton X-100 and 200  $\mu L$  tetraethoxysilane (TEOS) was prepared in a breaker, in the meantime, the POM (0.024g) suspended in 1 mL H<sub>2</sub>O was mixed with the other microemulsion containing 9.29 mL cyclohexane, 2.26 mL n-octanol, 2.23 mL Triton X-100 and 200  $\mu L$  ammonia. The two microemulsions were mixed under moderate stirring at room temperature for 24 h, after that, acetone was added to precipitate the nanoparticles. The obtained white solid was washed with ethanol after centrifuging at 8000 rpm. The POM@SiO<sub>2</sub> nanocomposites were dried in a desiccator under vacuum.

### Characterization of POM@SiO<sub>2</sub> nanocomposites

The morphology of nanocomposites were analyzed by a transmission electron microscopy (TEM, JEM-1011) operating at an acceleration voltage of 100 kV and the POM-based particles were deposited on carbon-coated copper grids. The hydrodynamic diameter of nanoparticles was determined by dynamic light scattering (DLS) (Brookhove) analysis. The IR peaks of the nanoparticles were identified by fourier transform infrared spectroscopy (Perkin Elmer

Spectrum RX-1) with the frequency range spanning from 2500 to 400  $\text{cm}^{-1}$ . The samples were prepared in the form of potassium bromide (KBr) pellets.

### Entrapment and *in vitro* release of POMs studies

The upload efficiency and *in vitro* release of POMs within the nanoparticles was determined by inductively coupled plasma mass spectrometry (ICP-MS) analysis. The *in vitro* release of POMs was performed in phosphate buffered saline (pH 5.5 and pH 7.4) at room temperature. The nanoparticles were incubated in 1.5 mL PBS buffer solution, at predetermined time intervals, the nanocomposites were centrifuged at 8000 rpm for 5 min, then 0.5 mL of the supernatant was taken out. After that, the pellet was redispersed and the same volume of PBS was supplemented. The supernatant was analyzed by the ICP-MS analysis. The entrapment efficiency was calculated by all the  $\text{AsMo}_6$  released from the  $\text{SiO}_2$  shell. It was determined by the following formulae:

$$\text{Entrapment efficiency} = \frac{M_{np}}{M_f} \times 100\% \quad (\text{Eq 1})$$

where  $M_{np}$  is the mass of  $\text{AsMo}_6$  in the nanocomposites,  $M_f$  is the mass of POMs used in the formulation.

### Cytotoxicity studies

The breast cancer cells MCF-7 (provided by the department of the 1<sup>st</sup> hospital, Jilin University) were cultured in RPMI 1640 medium (Hyclone) supplemented with 10% (V/V) fetal bovine serum (FBS, Hyclone) and 50 U/mL penicillin-streptomycin in 5% carbon dioxide atmosphere at 37°C in an incubator. The medium was changed every other day and the cells were sub-cultured after attaining about 80% confluency.

The antitumor activity of the nanoparticles was tested by the MTT assay. Briefly, The MCF-7 cells were seeded into a 96-well plate at a density of  $1 \times 10^4$  cells/well. After incubating the cells for 24 h, the dilutions of POM@ $\text{SiO}_2$  nanocomposites at different doses (containing real concentrations of POM 2.5–80  $\mu\text{g}/\text{mL}$  at specific intervals) were added and incubated for 24 h, 48 h and 72 h. After that, the culture medium was discarded and the wells were washed with PBS twice, followed by the addition of 20  $\mu\text{L}$  MTT dye (0.5 mg/mL) each well. The cells were incubated for another 4 h at 37°C. After removing all the culture medium, 150  $\mu\text{L}$  DMSO was added per well. The percentage of cell viability was measured on a microplate reader (Biotek Co., USA) at the wavelength of 490 nm. The cell inhibitory rate was calculated using the following equation:

$$\text{Inhibitory rate (\%)} = (1 - OD_{\text{treatment}} / OD_{\text{control}}) \times 100\% \quad (\text{Eq 2})$$

### Morphological observation

To observe the morphological changes on MCF-7 cells by the nanoparticles, cells were seeded in confocal culture dishes for 24 h at 37°C, after that, cells were treated with POM@ $\text{SiO}_2$  nanocomposites. The cells were then stained with Hoechst 33342/PI solution (1:1, V/V) at room temperature for 10 min in the dark. The cellular morphology was observed using the fluorescence confocal microscopy (Olympus FV1000, Japan).

### Flow cytometry analysis of cell apoptosis

MCF-7 cells were placed on a 12-well plate for 24 h. The nanoparticles solution with a corresponding POM concentration of 80  $\mu\text{g}/\text{mL}$  was then added and incubated at 37°C. After 24 h,

the cells were harvested and then washed three times with cold PBS. After centrifugation, the supernatant was discarded, and the pellets were resuspended in Annexin-V-FITC/PI buffer and left in the dark for 15 min at room temperature. Cells were analyzed on a flow cytometer using Cell Quest Software. Only single cells were gated for fluorescence analysis.

### Flow cytometry analysis of cell cycle distribution

Briefly, MCF-7 cells were seeded into a 12-well plate ( $1 \times 10^6$  cells per well) at  $37^\circ\text{C}$  for 24 h. After that, they were exposed to different concentrations of the nanoparticles (corresponding POM concentrations of 80, 40 and 20  $\mu\text{g}/\text{mL}$ ). The cells were harvested using trypsin and collected by centrifugating at 1200 rpm, then, washed three times with cold PBS. After that, Triton X-100 (0.1%, 100  $\mu\text{L}$ ), DNase free RNase (200  $\mu\text{g}/\text{mL}$ , 100  $\mu\text{L}$ ) and propidium iodide (50  $\mu\text{g}/\text{mL}$ , 200  $\mu\text{L}$ ) were added to the cells. The cells were incubated for 30 min at room temperature in dark.

### Western blot

After treatment of POM@SiO<sub>2</sub> nanoparticles for 24 h, total cellular proteins were prepared using RIPA lysis buffer from MCF-7 cells. The protein concentrations were established by bicinchoninic acid (BCA) assay. Equal amount of protein was separated by 12% polyacrylamide gels (SDS-PAGE) and then transferred onto nitrocellulose membranes. The membranes were blocked with 5% milk at  $4^\circ\text{C}$  overnight and then incubated with specific primary antibodies. After washing with TBST (containing 0.1% Tween 20) 3 times, the membranes were incubated with the corresponding HRP-conjugated secondary antibodies in TBST at  $37^\circ\text{C}$  for 1 h. The protein  $\beta$ -actin was used as a housekeeping control for normalization. Finally, the expression levels of proteins were visualized and analyzed using ImageJ software.


### HSA binding experiments

**UV-vis absorption spectra.** The absorption spectra of 4 mg/mL POM@SiO<sub>2</sub> nanoparticles, 2.5  $\mu\text{M}$  HSA and the mixture of them were measured by a UV spectrophotometer at room temperature. The absorption spectra was set from 190 to 600 nm, 10.0 mm optical path length quartz cuvette was used in this test.

**Fluorescence titration experiments.** The absorption titration experiments were performed by sequential addition of specified volume of POM@SiO<sub>2</sub> nanoparticles stock solution into HSA solution. Quartz cuvette with 10.0 mm optical path length was used. Excitation of the sample took place at a wavelength of 290 nm and the emission spectra were recorded from 300 to 450 nm. The concentration of HSA was 2.5  $\mu\text{M}$ , whereas the nanocomposites concentrations increased stepwise from 0 to 0.04  $\mu\text{g}/\text{mL}$ . At the same time, by fixing the excitation wavelength and emission wavelength at a  $\Delta\lambda$  value of 60 nm, the synchronous fluorescence intensity of the mixture solution (POM@SiO<sub>2</sub> nanoparticles and HSA) was detected. The widths of the slits were all 5.0 nm.

### Statistical analysis

All statistical analyses were performed using the SPSS Version 17.0 for Windows (significance was established at  $P < 0.05$ ). Data were expressed as mean  $\pm$  SD (standard deviation), statistical significance was evaluated by one-way analysis of variance (ANOVA) combined with Duncan's multiple range tests. All experiments were performed in triplicate, unless otherwise indicated.



**Fig 1. Schematic of the synthesis of POM@SiO<sub>2</sub> nanoparticles using in the antitumour procedure.**

<https://doi.org/10.1371/journal.pone.0181018.g001>


## Results and discussions

### Synthesis and characterization of the POM@SiO<sub>2</sub> nanoparticles

The POM@SiO<sub>2</sub> nanoparticles were obtained by the hydrolysis of tetraethoxysilane (TEOS) method (Fig 1). The TEM image showed morphological uniform nanosized spheres (Fig 2A), which provided direct evidence of the formation. It is clearly evident from the image that nearly monodispersed POM@SiO<sub>2</sub> nanoparticles were obtained by this technique, the average particle diameters were about 39 nm. The POMs were encapsulated in SiO<sub>2</sub> with an evident core/shell structure. EDX mapping confirmed the presence of arsenic and molybdenum from POM and the presence of silica from the shell (S1 Fig). As shown in Fig 2B that the hydrodynamic diameter of POM@SiO<sub>2</sub> nanoparticle solution was between 30 and 52 nm by the dynamic light scattering (DLS) measurements. The image was supported by the above transmission electron microscopy (TEM) observation. Particles between 33 and 43 nm reached about 48%. These results also demonstrated the reduction of POM aggregation due to the encapsulation. The FT-IR spectra (Fig 2C) of the POM exhibited the absorption characteristic peaks at 928, 688, 538 and 426 cm<sup>-1</sup>, which were attributed to  $\nu(\text{Mo-O}_{\text{bridge}}\text{-Mo})$  and  $\nu(\text{Mo-O}_{\text{terminal}})$  of polyoxoanion as described in the previous study [39], the corresponding peaks were exhibited in the POM@SiO<sub>2</sub> solid line as shown in the image (860, 617, 546, 430 cm<sup>-1</sup>), indicating that these compounds still retain the basic structure after encapsulated in SiO<sub>2</sub>. The strong absorption band at 1110 cm<sup>-1</sup> as shown in the POM@SiO<sub>2</sub> line was attributed to the Si-O stretching, which further demonstrated the formation of POM@SiO<sub>2</sub> nanoparticles.

To characterize the release of POMs, the POM@SiO<sub>2</sub> nanoparticles were incubated at pH values of 5.5 and 7.4 PBS solutions. The nanoparticles were centrifuged at predetermined time intervals and analyzed by ICP-MS. From these releasing profile studies (Fig 2D), the AsMo<sub>6</sub>






**Fig 2. Characterization and release efficiency of the POM@SiO<sub>2</sub> nanoparticles.** (a) TEM images of AsMo<sub>6</sub>@SiO<sub>2</sub> nanoparticles. The scale bar is 100 nm. (b) DLS measurement image of the nanoparticles. (c) FT-IR spectra of AsMo<sub>6</sub> (dash line) and nanoparticles (solid line). (d) The release efficiency of nanoparticles at pH 7.4 and 5.5. Results represent the mean ± SD from three independent experiments.

<https://doi.org/10.1371/journal.pone.0181018.g002>

was slowly released from the nanoparticles at every detecting point. At the point of 25 h, 16.1% was released from the particles in pH 7.4 PBS and 23.8% in pH 5.5 PBS. At the point of 60 h, reached about 34% and 42%, respectively. The release efficiency increased stepwise during the intervals and the SiO<sub>2</sub> resulting in the controlled release from the shells. Efficiency at pH 5.5 was a little higher than that at pH 7.4. Entrapment efficiency was calculated by all the POMs which released from the nanocomposites. The entrapment efficiency of POM within the nanoparticles was calculated to be 42.6%.

### Anticancer activity studies

To determine whether the doped POMs nanoparticles could enhance their antitumour activity, experiments were performed *in vitro* at different concentrations by MTT assay on MCF-7 cells. As shown in Fig 3, the nanoparticles showed significant cytotoxicity to MCF-7 cells at a concentration of 40 µg/mL (calculated by the encapsulated POM) with the cell viability about 51.9%, the anti-proliferative effects were dependent on its concentration. The cell viability was down to 31.3% at 24 h, 1.7% at 48 h and still kept about 2.0% at 72 h with POM concentration of 80 µg/mL that contained in the nanoparticles. The IC<sub>50</sub> value of the corresponding POM concentration in the POM@SiO<sub>2</sub> nanoparticles was calculated to be 40 µg/mL at 24 h, 10.8 µg/mL at 48 h, 1.7 µg/mL at 72 h. Particles showed antitumor activity in a time dependent manner in these three periods. For one reason, the cells took more particles and the drug exhibited more antitumor effect with longer time during a specific time frame, which could enhance the



**Fig 3. Nanoparticles show antitumor activity in a time and dose dependent manner.** Cytotoxicity analysis of POM@SiO<sub>2</sub> nanoparticles on MCF-7 cells by MTT at different doses. The POM concentration was calculated by the encapsulate efficiency of the nanoparticles. Data are presented as the mean ± SD of three independent experiments. \*P < 0.05 for the nanoparticles at different doses vs. control.


<https://doi.org/10.1371/journal.pone.0181018.g003>

cytotoxicity. For the other, the SiO<sub>2</sub> shells encapsulated the drug inside, which could control and decrease the release efficiency of POM as mentioned in the drug release experiment. At the point of 48 h, the release efficiency was about 37% at pH 5.5 and the drug showed significant antitumor activity to cells at the biggest drug concentration. In this way, the nanoparticles showed enhanced cytotoxicity during the long period as detected at different intervals. On the other hand, as shown in S2A Fig, the pure POM solution with the same concentration that contained in the particles exhibited nearly no cytotoxicity on MCF-7 cells. The IC<sub>50</sub> value of the plain drug was calculated to be 2.0 × 10<sup>4</sup> µg/mL (S2B Fig), which was much larger than that according to the nanoparticles. At the concentration of 1.8 × 10<sup>4</sup> µg/mL, the cell viability was 33.6%. For the SiO<sub>2</sub> shells account for most mass of the particles, the cytotoxicity of the corresponding concentration shells was performed. The SiO<sub>2</sub> at the same concentration which performed in the cytotoxicity study of the nanoparticles showed little antitumor effect (S3 Fig). The cell viability was 79.9%, 69.5%, 66.5% comparing to that of 63.2%, 51.8% and 31.3% as shown in results of the nanoparticles. It can be concluded that the antitumor activity of the POM@SiO<sub>2</sub> nanoparticles is higher than the free POM.

### Hoechst 33342/PI double staining assay

Hoechst 33342/PI double staining assay was performed to detect the necrotic cell by confocal laser scanning microscopy (Fig 4). The nuclei of normal cells can be stained into light blue (Hoechst 33342), apoptotic cells can be stained into brilliant blue and light red (Hoechst 33342 and PI) and the dead cells were brilliant red (PI). The results were presented in the CLSM





**Fig 4. Hoechst 33342/PI dye shows the normal and dead cells.** MCF-7 cells treated with POM@SiO<sub>2</sub> nanoparticles (corresponding POM concentration of 80 µg/mL) at 24 h and stained with Hoechst 33342/PI dye. Scale bar is 60 µm (Original magnification 20 ×).

<https://doi.org/10.1371/journal.pone.0181018.g004>

images. In the control group, nuclei were all stained into blue and no red cells appeared in the image. In the presence of POM@SiO<sub>2</sub> nanoparticles, the cell numbers reduced dramatically and there were a large number of necrotic cell residues (stained into red by PI). Massive necrotic and apoptotic cells were found in the drug group at the corresponding POM concentration of 40 µg/mL. The number of dead cells were increased with the adding of nanoparticles. Therefore, it can be concluded that the nanoparticles inhibit this cell line growth significantly. The changes of nuclei and cells morphology become much clearer under the magnification of 60 (S4 Fig). Cells in the control groups nested very well and grew strongly at a high density (bright images of DIC channel). Comparing to the intact and polygonal shape in the control group, cells exposed to the nanocomposites showed shrink margin loss of contact with the adjacent ones and apparently the sharp decrease in amount. Hoechst 33342/PI cytological investigations elucidated the membrane instability and cytoskeleton disturb effect by the nanoparticles.

### Flow cytometry analysis of cell apoptosis


To further confirm and detect the apoptosis effect on MCF-7 cells induced by the nanoparticles, Annexin V-FITC /propidium iodide (PI) double-staining technique was used. It is sensitive to detect the early apoptosis phase cells based on distinct double staining patterns: viable (Annexin V- and PI-, lower left square), early apoptotic (Annexin V+ and PI-, lower right square), late apoptotic (Annexin V+ and PI+, upper right square) and necrotic cells (Annexin V- and PI+, upper left square). The results (Fig 5) showed that the proportion of late apoptotic cells increased with the addition of the nanoparticles. The proportion of late apoptotic cells induced by the nanoparticles is nearly 34% higher than the control group (5.71% in control group, 39.47% in drug group). Taken together, the POM@SiO<sub>2</sub> nanoparticles induced the apoptosis of MCF-7 cells and inhibited their proliferation, which were consistent with the MTT results mentioned above.

### Flow cytometric analysis for cell cycle distribution

To detect whether the growth inhibition of MCF-7 cells by nanoparticles is a result of cell cycle arrest, MCF-7 cells were seeded and exposed to different concentrations of the POM@SiO<sub>2</sub> nanoparticles (corresponding POM concentrations of 20, 40, 80 µg/mL) for 24 h, stained with PI and examined by FCM to analyze the changes of cell cycle. Generally, a doubling of DNA and other cellular contents are necessary for a cell replication process. Cell cycle distribution is divided into four distinct phases: G<sub>1</sub> phase, S phase, G<sub>2</sub> phase and M phase, which are defined by cell entry checkpoints. The major event of S phase is the synthesis of DNA. The cell prepares to divide during G<sub>2</sub> phase and division takes place during M phase. Passing these checkpoints, the cell will proceed with division. External factors such as drugs (5-fluorouracil), radiation, and reactive oxygen species result in DNA-damage-related cell death during S phase [42, 43]. The abnormality of DNA prevents the progress of replication and influences the next new one. Then the DNA repair occurs during the G<sub>2</sub> phase, before entering the M phase for mitosis. For the cell cycle analysis, as shown in Fig 6, the results showed increase level in S phase from 26.73% in the control group to 30.41%, 33.58%, 32.81%, respectively with the corresponding reduction in G<sub>1</sub> and G<sub>2</sub>/M phase. The level of G<sub>1</sub> phase was 66.1%, 62.04%, 59.86% and 59.58%, respectively, which suggested the inhibition mechanism on MCF-7 cells was S phase arrest. Since DNA replication occurs during S phase, DNA damage is responsible for S phase arrest as well as the inhibition of proliferation versus the control group.


### Western blot

The flow cytometry analysis indicated that the apoptosis rate increased in MCF-7 cells as the POM@SiO<sub>2</sub> nanoparticles concentration increased. To further confirm the effects of nanoparticles in MCF-7 cells, western blot assay was performed to investigate the molecular mechanism for the observed apoptosis. As shown in Fig 7, a remarkable upregulation of cleaved caspase 3 protein levels and a decrease of Bcl-2 protein levels were observed as the nanoparticle concentration increased. As we know Bcl-2 is an apoptosis inhibitor which could restrain cell apoptosis. The cleaved caspase 3/β-actin ratio in MCF-7 cells treated with nanoparticles (corresponding POM concentration of 80 µg/mL) was 0.616, which was significantly higher than that of the blank control. Therefore, our findings showed that nanoparticles could promote apoptosis by inhibiting the Bcl-2 protein and upregulating the cleaved caspase 3 expression in cells.



**Fig 5. Annexin V-FITC/PI analysis of apoptosis in MCF-7 cancer cells induced by POM@SiO<sub>2</sub> nanoparticles.** The corresponding POM concentration is 80 µg/mL. Cells were incubated with nanoparticles for 24 h. The lower-right panel presents early apoptotic cells, whereas the upper-right panel displays late apoptotic cells. (a) The control group. (b) The POM@ SiO<sub>2</sub> treated group.

<https://doi.org/10.1371/journal.pone.0181018.g005>




**Fig 6. Cell cycle arrest effect of nanoparticles on MCF-7 cells.** (a) Cells were treated with POM@SiO<sub>2</sub> nanoparticles (corresponding POM concentration of 20, 40, 80 µg/mL) for 24 h. The distribution of cell cycle was detected by FCM with PI staining. The percentages of G<sub>1</sub>, S, G<sub>2</sub> phase were calculated using ModFit LT software. (b) Statistical results of S phase cells. Results represent the mean ± SD from three independent experiments. \*P < 0.05 for G<sub>1</sub> phase vs. control. \*\*P < 0.01 for S phase vs. control.

<https://doi.org/10.1371/journal.pone.0181018.g006>

### HSA binding

**UV-vis absorption.** UV-vis measurement is an easy and effective way to investigate the structural changes and complex formation between the protein and nanoparticles [44]. As shown in Fig 8, the characteristic absorption peaks of isolate HSA were 206 nm and 278 nm, meanwhile isolate POM@SiO<sub>2</sub> nanoparticles were found near 200 nm at the same concentration. With the addition of nanoparticles solution, the absorption peak of the protein was slightly increased, which indicated that an interaction occurred between HSA and POM@SiO<sub>2</sub> nanoparticles.




**Fig 7. Effect of POM@SiO<sub>2</sub> on the expressions of β-actin, Bcl-2, and cleaved caspase 3 proteins.** The MCF-7 cells were treated with different concentrations of POM@SiO<sub>2</sub> nanoparticles (corresponding POM concentration of 20, 40, 80 µg/mL) for 24 h. The nanoparticles induced apoptosis by inhibiting the Bcl-2 protein.

<https://doi.org/10.1371/journal.pone.0181018.g007>

### Fluorescence spectroscopic experiments

The fluorescence measurements can be applied to investigate the binding information of small molecule substances to protein, such as the binding mechanism, binding constants, binding mode, and the number of binding sites. Fluorescence quenching is the decrease of quantum



**Fig 8. Effect of nanocomposites on the absorption spectra of HSA.** (a) UV-vis spectra of 2.5 µM HSA, (b) POM@SiO<sub>2</sub> nanoparticles (4 mg/mL) and (c) nanoparticles-HSA complex.

<https://doi.org/10.1371/journal.pone.0181018.g008>

yield from a fluorophore induced by quencher molecule, there are variety molecular interactions between them, such as excited-state reaction, energy transfer and collision quenching. That means the fluorescence changes can give information about the molecular micro-environment. And in another level, changes in emission spectra of residues is often considered in the investigation of protein folding and association reactions [5, 45]. Fluorescence quenching is a well-established method to study the interactions between ligand and protein. It has been used to analyze the interactions between different POMs and HSA [46–50]. But all of these investigations were previously performed between plain POMs and protein. In this study, the interaction between POM uploading silica nanoparticles and HSA was performed.

HSA belongs to endogenous fluorophores with tryptophan residue at position 214 nm in the molecule. In these steady state fluorescence experiments, the concentration of HSA was kept constant, while the concentration of nanoparticles was increased stepwise. The fluorescence emission spectra of the complexes in the absence and presence of HSA were shown in Fig 9A. [51]. Fluorescence intensity of HSA decreased regularly at about 330 nm with the enhancement of nanoparticles (fluorescence quenching), which indicated that particle interacted with HSA and a complex is formed between them [45]. Furthermore, there was a red shift at the maximum emission peaks of HSA after the addition of particles, which suggested that the fluorescing residues in nonpolar hydrophobic cavities are moved to a hydrophilic environment [5].

In the case of fluorescence quenching procedures, the absorption of nanoparticles can absorb protein fluorescence and the presence of particles can scatter the input and output fluorescence, further reducing the fluorescence signal, which are termed as inner filter effect (IFE). This also results in a decreased fluorescence intensity that is not a quenching effect. In this study, the following formula was used for correcting fluorescence intensity:

$$F_{cor} = F_{obs} \times 10^{(A_{ex}+A_{em})/2} \tag{Eq 3}$$


where  $F_{cor}$  and  $F_{obs}$  are the correct and observed fluorescence intensity, respectively.  $A_{ex}$  and  $A_{em}$  are the absorbance value at the excitation and emission wavelengths, respectively. Fluorescence intensities were corrected for inner filter and dilution effects before the following analysis [45, 52].

There are two possible reasons for the complexes quenching HSA fluorescence, the static quenching and dynamic quenching. The analysis of the results was done with the help of Stern-Volmer equation [53]:

$$F_0/F = 1 + K_q \tau_0 [D] = 1 + K_{sv} [D] \tag{Eq 4}$$

where  $F_0$  and  $F$  are the fluorescence intensity in the absence and presence of a quencher, respectively,  $[D]$  is the concentration of quencher,  $K_q$  and  $K_{sv}$  are the quenching rate constant, Stern-Volmer dynamic quenching constant, respectively,  $\tau_0$  is the average lifetime of molecule without the quencher and its value is  $10^{-8}$  s. Based on the experimental data, the Stern–Volmer plot for the quenching of HSA with POM@SiO<sub>2</sub> nanoparticles was given in the inset of Fig 8A. If the quenching process is the dynamic one, the dependence of  $F_0/F$  on the quencher concentration is linear with slope equal to the value of  $K_{sv}$ . Moreover, the maximum quenching rate constant of various quenchers is  $2.0 \times 10^{10}$  Lmol<sup>-1</sup>s<sup>-1</sup>. The fluorescence quenching coefficient of the POM@SiO<sub>2</sub> is  $1.3 \times 10^{18}$  Lmol<sup>-1</sup>s<sup>-1</sup>, which is far greater than the  $K_q$  value of the dynamic quenching for various quenchers. It suggested that the quenching belonged to a static quenching rather than the dynamic one. In static quenching, small molecules bind to equivalent sites on a macromolecule independently; whereas in the dynamic interaction, the quencher binds to the fluorophore during the excited state [5]. Furthermore, static quenching often changes





**Fig 9. Fluorescence quenching and binding effect study of the nanocomposites.** (a) Fluorescence spectra of HSA (2.5  $\mu\text{M}$ ) in the presence of different concentrations of nanoparticles. The arrow shows the fluorescence intensity changes upon increasing concentration of nanoparticles. Inset: Stern-Volmer plot of the fluorescence titration data of HSA with different concentrations of nanocomposites in PBS at room temperature ( $[\text{POM@SiO}_2] = 0, 0.125, 0.25, 0.5, 1, 2, 4 \times 10^{-2} \mu\text{g/ml}$ ). (b) The synchronous fluorescence spectra of HSA (0.02503B0043M) in the presence of different concentrations of nanoparticles at  $\Delta\lambda = 60 \text{ nm}$ .

<https://doi.org/10.1371/journal.pone.0181018.g009>

absorption spectrum of the luminophore molecule, while dynamic quenching is on the contrary. According to the UV-vis analyses, the absorption spectrum of HSA was changed by the POM@SiO<sub>2</sub>. Therefore, the fluorescence quenching of the nanoparticles was static quenching and the nanoparticles were likely to bind to HSA. These results indicated the interaction between POM@SiO<sub>2</sub> nanoparticles and HSA molecules, and the nanospheres can be transported in the serum albumin.

To further study the binding effect of nanoparticles to HSA, synchronous fluorescence (SFS) study was performed. The test could provide the information of tryptophan residue of the protein when the wavelength interval was established in 60 nm [33]. Fig 9B showed that the fluorescence intensities of tryptophan residue were decreased as the nanoparticle solutions added stepwise to HSA stock solution. The emission wavelength peak of tryptophan residue in the investigated concentration range was a slightly blue shift ( $\Delta\lambda = 60 \text{ nm}$ ). It suggested that the nanoparticles changed the conformation of the protein.

## Conclusions

In summary, we report the *in vitro* anti-proliferative effects on MCF-7 cells of the POM@SiO<sub>2</sub> nanoparticles with small size around 40 nm. The nanoparticles significantly enhanced the cytotoxicity on the cells comparing to that of the pure POM. SiO<sub>2</sub> shells controlled the release efficiency as the drug delivery system. The higher antitumor activity could be due to their higher cellular penetration for the small size and surface modification by the shells. The Flow cytometry analysis results showed that the nanoparticles could induce apoptosis and cell cycle S phase arrest. The HSA binding experiment showed that the complex changed the conformation and quenched the fluorescence of the protein, which belonged to a static quenching. Furthermore, the antitumour effect of other cell lines and modification with target molecules on the spheres should be further investigated.

## Supporting information

**S1 Fig. EDX mapping images of POM@SiO<sub>2</sub> nanocomposites.** TEM image in dark field mode (a) and EDX mapping for Si (green) (b), As (red) (c) and Mo (blue) (d). The scale bar is 50 nm. (TIF)



**S2 Fig. The inhibitory effect of plain POM solution on MCF-7 cells at 24 h.** (a) Cell viability of the corresponding concentration performed in the cytotoxicity investigation of the nanoparticles. (b) Cell viability of higher concentration of plain POM. Results represent the mean  $\pm$  SD from three independent experiments. \* $P < 0.05$  for POM vs. control.

(TIF)

**S3 Fig. The inhibitory effect of pure SiO<sub>2</sub> MCF-7 cells at 24 h.** The SiO<sub>2</sub> at the same concentration performed in the cytotoxicity study of the nanoparticles showed low antitumor effect.

(TIF)

**S4 Fig. Morphological changes of MCF-7 cells treated with POM@SiO<sub>2</sub> nanoparticles at 24 h.** The corresponding POM concentration was 80  $\mu\text{g/mL}$ . Scale bar in the CLSM is 40  $\mu\text{m}$  (Original magnification 60 $\times$ ). Arrow shows apoptotic nuclear.

(TIF)

## Acknowledgments

This work was financially supported by NSFC (81402719), Young Scholars Program of Norman Bethune Health Science Center of Jilin University (2013202015), and Norman Bethune Program of Jilin University (2015228).

## Author Contributions

**Data curation:** Hongqian Cao, Rui Tian.

**Formal analysis:** Hongqian Cao.

**Investigation:** Wei Yang.

**Methodology:** Chunyan Li, Wen Qi, Xiangjun Meng.

**Project administration:** Yanfei Qi.

**Resources:** Juan Li.

**Validation:** Wei Yang.

**Visualization:** Yanfei Qi, Juan Li.

**Writing – original draft:** Hongqian Cao.

**Writing – review & editing:** Hongqian Cao.

## References

1. Cui YX, Bradbury R, Flamini V, Wu B, Jordan N, Jiang WG. MicroRNA-7 suppresses the homing and migration potential of human endothelial cells to highly metastatic human breast cancer cells. *Br J Cancer*. 2017. <https://doi.org/10.1038/bjc.2017.156> PMID: 28571043
2. Tao Z Q SA, Lu C, et al. Breast cancer: epidemiology and etiology. *Cell biochemistry and biophysics*. 2015; 72(2):333–8. <https://doi.org/10.1007/s12013-014-0459-6> PMID: 25543329
3. Elomrani F, Zine M, Afif M, L'annaz S, Ouziane I, Mrabti H, et al. Management of early breast cancer in older women: from screening to treatment. *Breast Cancer: Targets and Therapy*. 2015; 7:165.
4. Siegel RL, Miller KD, Jemal A. Cancer Statistics, 2016. *Ca-Cancer J Clin*. 2016; 66(1):7–30. <https://doi.org/10.3322/caac.21332> PMID: 26742998
5. Tanzadehpanah H, Asoodeh A, Saberi MR, Chamani J. Identification of a novel angiotensin-I converting enzyme inhibitory peptide from ostrich egg white and studying its interactions with the enzyme. *Innovative Food Science & Emerging Technologies*. 2013; 18:212–9. <https://doi.org/10.1016/j.ifset.2013.02.002>.

6. Dianat S, Bordbar AK, Tangestaninejad S, Yadollahi B, Amiri R, Zarkesh-Esfahani SH, et al. In vitro antitumor activity of free and nano-encapsulated  $\text{Na}_5[\text{PMo}_{10}\text{V}_2\text{O}_{40}]\cdot n\text{H}_2\text{O}$  and its binding properties with ctDNA by using combined spectroscopic methods. *J Inorg Biochem.* 2015; 152:74–81. <https://doi.org/10.1016/j.jinorgbio.2015.08.015> PMID: 26360100
7. Mizuno N, Yamaguchi K, Kamata K. Epoxidation of olefins with hydrogen peroxide catalyzed by polyoxometalates. *Coordin Chem Rev.* 2005; 249(17–18):1944–56. <https://doi.org/10.1016/j.ccr.2004.11.019>
8. Hill CL. Progress and challenges in polyoxometalate-based catalysis and catalytic materials chemistry. *J Mol Catal a-Chem.* 2007; 262(1–2):2–6. <https://doi.org/10.1016/j.molcata.2006.08.042>
9. Kamata K, Yonehara K, Sumida Y, Yamaguchi K, Hikichi S, Mizuno N. Efficient epoxidation of olefins with > 99% selectivity and use of hydrogen peroxide. *Science.* 2003; 300(5621):964–6. <https://doi.org/10.1126/science.1083176> PMID: 12738860
10. Du DY, Qin JS, Li SL, Lan YQ, Wang XL, Su ZM. 3d-4f Heterometallic Complexes for the Construction of POM-based Inorganic-Organic Hybrid Compounds: from Nanoclusters to One-Dimensional Ladder-Like Chains. *Aust J Chem.* 2010; 63(9):1389–95.
11. Muller A, Peters F, Pope MT, Gatteschi D. Polyoxometalates: Very large clusters—Nanoscale magnets. *Chem Rev.* 1998; 98(1):239–71. <https://doi.org/10.1021/cr9603946> PMID: 11851505
12. Rhule JT, Hill CL, Judd DA. Polyoxometalates in medicine. *Chem Rev.* 1998; 98(1):327–57. <https://doi.org/10.1021/cr960396q> PMID: 11851509
13. Kortz U, Muller A, van Slageren J, Schnack J, Dalal NS, Dressel M. Polyoxometalates: Fascinating structures, unique magnetic properties. *Coordin Chem Rev.* 2009; 253(19–20):2315–27. <https://doi.org/10.1016/j.ccr.2009.01.014>
14. Pope MT. Anion Guests in Heteropolyanions. *Nature.* 1992; 355(6355):27-. <https://doi.org/10.1038/355027a0>
15. Casan-Pastor N, Gomez-Romero P. Polyoxometalates: From inorganic chemistry to materials science. *Front Biosci.* 2004; 9:1759–70. <https://doi.org/10.2741/1365> PMID: 14977584
16. NV Izarova MP, Kortz U. Edelmetalle in Polyoxometallaten. *Angewandte Chemie-International Edition.* 2012; 124(38):9630–49. <https://doi.org/10.1002/ange.201202750>
17. Dolbecq A, Dumas E, Mayer CR, Mialane P. Hybrid Organic-Inorganic Polyoxometalate Compounds: From Structural Diversity to Applications. *Chem Rev.* 2010; 110(10):6009–48. <https://doi.org/10.1021/cr1000578> PMID: 20666374
18. Yamase T. Polyoxometalates for molecular devices: antitumor activity and luminescence. *Molecular Engineering.* 1993; 3(1–3):241–62.
19. Yamase T, Fujita H, Fukushima K. Medical chemistry of polyoxometalates. Part 1. Potent antitumor activity of polyoxomolybdates on animal transplantable tumors and human cancer xenograft. *Inorg Chim Acta.* 1988; 151(1):15–8.
20. Dianat S, Bordbar AK, Tangestaninejad S, Yadollahi B, Zarkesh-Esfahani SH, Habibi P. ctDNA binding affinity and in vitro antitumor activity of three Keggin type polyoxotungstates. *J Photoch Photobio B.* 2013; 124:27–33. <https://doi.org/10.1016/j.jphotobiol.2013.04.001> PMID: 23648797
21. Wang XH, Liu JF, Li JX, Yang Y, Liu JT, Bin L, et al. Synthesis and antitumor activity of cyclopentadienyltitanium substituted polyoxotungstate  $[\text{CoW}_{11}\text{O}_{39}(\text{CpTi})]^{7-}$  (CP =  $\eta^5\text{-C}_5\text{H}_5$ ). *J Inorg Biochem.* 2003; 94(3):279–84. [https://doi.org/10.1016/S0162-0134\(02\)00631-1](https://doi.org/10.1016/S0162-0134(02)00631-1) PMID: 12628708
22. Liu JT, Lu YF, Fan SD. Synthesis, Spectroscopic Characterization and Antitumoral Activities of Cyclopentadienylvanadium Derivatives of Polyoxotungstates. *Spectrosc Spect Anal.* 2012; 32(9):2512–4. [https://doi.org/10.3964/j.issn.1000-0593\(2012\)09-2512-03](https://doi.org/10.3964/j.issn.1000-0593(2012)09-2512-03)
23. Wang XH, Liu JF. Synthesis and characterization of organotin substituted heteropolytungstophosphates and their biological activity. *J Coord Chem.* 2000; 51(1):73–82. <https://doi.org/10.1080/00958970008047080>
24. Wang XH, Liu JT, Li JX, Liu JF. Synthesis, characterization and in vitro antitumor activity of diorganometallo complexes gamma-Keggin anions. *Inorg Chem Commun.* 2001; 4(7):372–4. [https://doi.org/10.1016/S1387-7003\(01\)00166-6](https://doi.org/10.1016/S1387-7003(01)00166-6)
25. Wang XH, Dai HC, Liu JF. Synthesis, properties and biological activity of organotin decatungstophosphates, Part 2. *Transit Metal Chem.* 1999; 24(5):600–4. <https://doi.org/10.1023/A:1006943101527>
26. Gerth HUV, Rompel A, Krebs B, Boos J, Lanvers-Kaminsky C. Cytotoxic effects of novel polyoxotungstates and a platinum compound on human cancer cell lines. *Anti-Cancer Drug.* 2005; 16(1):101–6. <https://doi.org/10.1097/00001813-200501000-00015>
27. Lee CH, Cheng SH, Huang IP, Souris JS, Yang CS, Mou CY, et al. Intracellular pH-Responsive Mesoporous Silica Nanoparticles for the Controlled Release of Anticancer Chemotherapeutics. *Angew Chem Int Edit.* 2010; 49(44):8214–9. <https://doi.org/10.1002/anie.201002639> PMID: 20865709

28. Hasenknopf B. Polyoxometalates: Introduction to a class of inorganic compounds and their biomedical applications. *Front Biosci-Landmrk*. 2005; 10:275–87. <https://doi.org/10.2741/1527>
29. Mulvaney P, Liz-Marzan LM, Giersig M, Ung T. Silica encapsulation of quantum dots and metal clusters. *J Mater Chem*. 2000; 10(6):1259–70. <https://doi.org/10.1039/b000136h>.
30. Li L, Choo ESG, Liu ZY, Ding J, Xue JM. Double-layer silica core-shell nanospheres with superparamagnetic and fluorescent functionalities. *Chem Phys Lett*. 2008; 461(1–3):114–7. <https://doi.org/10.1016/j.cplett.2008.07.005>
31. Hu SH, Chen SY, Liu DM, Hsiao CS. Core/single-crystal-shell nanospheres for controlled drug release via a magnetically triggered rupturing mechanism. *Adv Mater*. 2008; 20(14):2690. <https://doi.org/10.1002/adma.200800193> PMID: 25213891
32. Slowing II, Trewyn BG, Giri S, Lin VSY. Mesoporous silica nanoparticles for drug delivery and biosensing applications. *Adv Funct Mater*. 2007; 17(8):1225–36. <https://doi.org/10.1002/adfm.200601191>
33. Green M, Harries J, Wakefield G, Taylor R. The synthesis of silica nanospheres doped with polyoxometalates. *J Am Chem Soc*. 2005; 127(37):12812–3. <https://doi.org/10.1021/ja0543200> PMID: 16159270
34. Hungerford G, Green M, Suhling K. Optical spectroscopy following the incorporation of a rare-earth containing (Eu) polyoxometalate into a sol-gel derived media. *Physical Chemistry Chemical Physics*. 2007; 9(45):6012–5. <https://doi.org/10.1039/b711555e> PMID: 18004414
35. Stöber W, Fink A, Bohn E. Controlled growth of monodisperse silica spheres in the micron size range. *Journal of colloid and interface science*. 1968; 26(1):62–9.
36. Ye ZQ, Tan MQ, Wang GL, Yuan JL. Novel fluorescent europium chelate-doped silica nanoparticles: preparation, characterization and time-resolved fluorometric application. *J Mater Chem*. 2004; 14(5):851–6. <https://doi.org/10.1039/b311905j>
37. Varshney A, Sen P, Ahmad E, Rehan M, Subbarao N, Khan RH. Ligand Binding Strategies of Human Serum Albumin: How Can the Cargo be Utilized? *Chirality*. 2010; 22(1):77–87. <https://doi.org/10.1002/chir.20709> PMID: 19319989
38. Kragghansen U. Molecular Aspects of Ligand-Binding to Serum-Albumin. *Pharmacol Rev*. 1981; 33(1):17–53. PMID: 7027277
39. Li CY, Qi W, Cao HQ, Qi YF, Zhang S, Xu SH, et al. BSA-binding properties and anti-proliferative effects of amino acids functionalized polyoxomolybdates. *Biomed Pharmacother*. 2016; 79:78–86. <https://doi.org/10.1016/j.biopha.2016.01.042> PMID: 27044815
40. Li CY, Cao HQ, Sun JH, Tian R, Li DB, Qi YF, et al. Antileukemic activity of an arsenomolybdate in the human HL-60 and U937 leukemia cells. *J Inorg Biochem*. 2017; 168:67–75. <https://doi.org/10.1016/j.jinorgbio.2016.12.002> PMID: 28013066
41. Granadeiro CM, Ferreira RAS, Soares-Santos PCR, Carlos LD, Trindade T, Nogueira HIS. Lanthanopolyoxotungstates in silica nanoparticles: multi-wavelength photoluminescent core/shell materials. *J Mater Chem*. 2010; 20(16):3313–8. <https://doi.org/10.1039/b919691a>
42. Preya UH, Lee KT, Kim NJ, Lee JY, Jang DS, Choi JH. The natural terthiophene alpha-terthienylmethanol induces S phase cell cycle arrest of human ovarian cancer cells via the generation of ROS stress. *Chem Biol Interact*. 2017; 272:72–9. <https://doi.org/10.1016/j.cbi.2017.05.011> PMID: 28506552
43. Rodríguez-Vargas JM, Ruiz-Magana MJ, Ruiz-Ruiz C, Majuelos-Melguizo J, Peralta-Leal A, Rodríguez MI, et al. ROS-induced DNA damage and PARP-1 are required for optimal induction of starvation-induced autophagy. *Cell Res*. 2012; 22(7):1181–98. <https://doi.org/10.1038/cr.2012.70> PMID: 22525338
44. Bi SY, Song DQ, Tian Y, Zhou X, Liu ZY, Zhang HQ. Molecular spectroscopic study on the interaction of tetracyclines with serum albumins. *Spectrochim Acta A*. 2005; 61(4):629–36. <https://doi.org/10.1016/j.saa.2004.05.028> PMID: 15649793
45. Rashidipour S, Naeeminejad S, Chamani J. Study of the interaction between DNP and DIDS with human hemoglobin as binary and ternary systems: spectroscopic and molecular modeling investigation. *Journal of Biomolecular Structure and Dynamics*. 2015; 34(1):57–77. <https://doi.org/10.1080/07391102.2015.1009946> PMID: 25692655
46. Goovaerts V, Stroobants K, Absillis G, Parac-Vogt TN. Molecular interactions between serum albumin proteins and Keggin type polyoxometalates studied using luminescence spectroscopy. *Physical Chemistry Chemical Physics*. 2013; 15(42):18378–87. <https://doi.org/10.1039/c3cp52848k> PMID: 24064593
47. Hungerford G, Hussain F, Patzke GR, Green M. The photophysics of europium and terbium polyoxometalates and their interaction with serum albumin: a time-resolved luminescence study. *Physical Chemistry Chemical Physics*. 2010; 12(26):7266–75. <https://doi.org/10.1039/b925547h> PMID: 20490399
48. Zhang G, Keita B, Craescu CT, Miron S, de Oliveira P, Nadjo L. Molecular interactions between Wells–Dawson type polyoxometalates and human serum albumin. *Biomacromolecules*. 2008; 9(3):812–7. <https://doi.org/10.1021/bm701120j> PMID: 18266320

49. Zhang GJ, Keita B, Brochon JC, de Oliveira P, Nadjo L, Craescu CT, et al. Molecular interaction and energy transfer between human serum albumin and polyoxometalates. *Journal of Physical Chemistry B*. 2007; 111(7):1809–14. <https://doi.org/10.1021/jp063758z> PMID: 17256886
50. Zheng L, Ma Y, Zhang GJ, Yao JN, Keita B, Nadjo L. A multitechnique study of europium decatungstate and human serum albumin molecular interaction. *Physical Chemistry Chemical Physics*. 2010; 12(6):1299–304. <https://doi.org/10.1039/b919952g> PMID: 20119607
51. Asoodeh A, Zardini HZ, Chamani J. Identification and characterization of two novel antimicrobial peptides, temporin-Ra and temporin-Rb, from skin secretions of the marsh frog (*Rana ridibunda*). *Journal of Peptide Science*. 2012; 18(1):10–6. <https://doi.org/10.1002/psc.1409> PMID: 21956830
52. Marouzi S, Sharifi Rad A, Beigoli S, Teimoori Baghaee P, Assaran Darban R, Chamani J. Study on effect of lomefloxacin on human holo-transferrin in the presence of essential and nonessential amino acids: Spectroscopic and molecular modeling approaches. *International Journal of Biological Macromolecules*. 2017; 97:688–99. <https://doi.org/10.1016/j.ijbiomac.2017.01.047> PMID: 28115228
53. Dewey TG. *Biophysical and biochemical aspects of fluorescence spectroscopy*: Springer; 1991.